Misplaced Pages

Duloxetine

Article snapshot taken from Wikipedia with creative commons attribution-sharealike license. Give it a read and then ask your questions in the chat. We can research this topic together.

This is an old revision of this page, as edited by Avb (talk | contribs) at 12:22, 18 January 2006 (updated links). The present address (URL) is a permanent link to this revision, which may differ significantly from the current revision.

Revision as of 12:22, 18 January 2006 by Avb (talk | contribs) (updated links)(diff) ← Previous revision | Latest revision (diff) | Newer revision → (diff)

Duloxetine chemical structure of duloxetine
Duloxetine

IUPAC chemical name
CAS number
 ?
ATC code
 ?
Chemical formula C18H19NOS, HCl
Molecular weight 333.38
Bioavailability ?
Metabolism Hepatic Oxidation
Elimination half-life 8-17 hours
Excretion 70% in urine, 20% in feces
Pregnancy category C (USA)
Legal status Prescription only (USA)
Routes of administration Oral

Duloxetine hydrochloride (brand names: Cymbalta/Yentreve) is a medically used drug that primarily targets major depressive disorders (MDD), pain related to diabetic peripheral neuropathy and stress urinary incontinence (SUI). Known also as LY248686, chemically (+)-(S)-N-methyl-3-(1-naphthyloxy)-
2-thiophenepropanamine, it is a potent dual reuptake inhibitor of serotonin (5-hydroxytryptamine, 5-HT) and norepinephrine (NE), possessing comparable affinities in binding to NE and 5-HT transport sites. Its behavior contrasts to most other dual-reuptake inhibitors in that Ki values are nearly 1:1.

Furthermore, duloxetine lacks affinity for monoamine receptors within the central nervous system. While there is limited data available regarding the pharmacokinetic profile of duloxetine in humans, its half-life is reported to be 10 to 15 hours. Most common side effects in clinical trials were nausea, somnolence, and dry mouth. In clinical trials weight gain was neutral compared to placebo. Ongoing studies including a 52 week safety and efficacy trial are available at www.lillytrials.com. Long-term side-effects seen in these trials did not vary from the original approval studies.

Duloxetine is also approved by the FDA for the treatment of diabetic neuropathy. Approved dosages for treatment diabetic peripheral neuropathic pain are 60mg and 120mg once daily.

When used for the treatment of depression, the approved dosage is 40mg-60 mg once daily. Duloxetine is available in capsules of 20mg, 30mg, and 60mg.

External links

Stub icon

This pharmacology-related article is a stub. You can help Misplaced Pages by expanding it.


Antidepressants (N06A)
Specific reuptake inhibitors and/or receptor modulators
SSRIsTooltip Selective serotonin reuptake inhibitors
SNRIsTooltip Serotonin–norepinephrine reuptake inhibitors
NRIsTooltip Norepinephrine reuptake inhibitors
NDRIsTooltip Norepinephrine–dopamine reuptake inhibitors
NaSSAsTooltip Noradrenergic and specific serotonergic antidepressants
SARIsTooltip Serotonin antagonist and reuptake inhibitors
SMSTooltip Serotonin modulator and stimulators
Others
Tricyclic and tetracyclic antidepressants
TCAsTooltip Tricyclic antidepressants
TeCAsTooltip Tetracyclic antidepressants
Others
Monoamine oxidase inhibitors
Non-selective
MAOATooltip Monoamine oxidase A-selective
MAOBTooltip Monoamine oxidase B-selective
Adjunctive therapies
Miscellaneous
Categories: